Assetmark Inc. Has $2.21 Million Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Assetmark Inc. raised its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 14.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 35,787 shares of the company’s stock after acquiring an additional 4,596 shares during the quarter. Assetmark Inc. owned approximately 0.07% of Amphastar Pharmaceuticals worth $2,213,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMPH. Commonwealth Equity Services LLC boosted its stake in shares of Amphastar Pharmaceuticals by 37.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 9,861 shares of the company’s stock valued at $454,000 after purchasing an additional 2,674 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Amphastar Pharmaceuticals by 18.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 7,036 shares of the company’s stock valued at $324,000 after purchasing an additional 1,082 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Amphastar Pharmaceuticals by 4.8% in the 3rd quarter. Teacher Retirement System of Texas now owns 10,967 shares of the company’s stock valued at $504,000 after purchasing an additional 507 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Amphastar Pharmaceuticals by 1.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 27,443 shares of the company’s stock valued at $1,262,000 after purchasing an additional 358 shares during the last quarter. Finally, Versor Investments LP bought a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at $262,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Michael A. Zasloff sold 12,500 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the completion of the sale, the director now owns 21,326 shares in the company, valued at $1,006,160.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 14,000 shares of company stock worth $655,145 over the last quarter. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $43.26 on Friday. The firm has a 50-day moving average of $42.10 and a 200-day moving average of $50.46. The company has a market cap of $2.12 billion, a P/E ratio of 14.97, a P/E/G ratio of 0.89 and a beta of 0.85. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.18 and a quick ratio of 1.72. Amphastar Pharmaceuticals, Inc. has a one year low of $38.43 and a one year high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.03). The firm had revenue of $178.11 million during the quarter, compared to analysts’ expectations of $174.90 million. Amphastar Pharmaceuticals had a net margin of 22.88% and a return on equity of 29.17%. Equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, May 13th. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday. Finally, JPMorgan Chase & Co. assumed coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $66.00.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.